Anthony  Bergmann net worth and biography

Anthony Bergmann Biography and Net Worth

Mr. Bergmann has served as Capricor Therapeutics’ Chief Financial Officer since 2018 and has been involved in the biotechnology industry for approximately 15 years. He joined Capricor in 2011 and has held roles of increasing responsibility, playing a key role in the Company’s strategic development and growth into a publicly traded biotechnology company. Mr. Bergmann oversaw Capricor’s entry into the public markets, including its reverse merger and subsequent uplisting to the Nasdaq Capital Market. He has also led equity financings totaling over $500 million to date as well as guided business development efforts resulting in multiple strategic partnerships throughout his tenure. Prior to Capricor, Mr. Bergmann was with Gettleson, Witzer and O’Connor, a Beverly Hills-based business and financial management firm, where he oversaw accounting and finance functions for several production studios with global box office revenue exceeding $1 billion. His clients included actors, musicians, directors, and international foundations in the entertainment industry. Prior to that he held roles in accounting, finance, and operations across start-ups and mid-sized companies. Mr. Bergmann earned his Bachelor of Science from Providence College and his M.B.A. from the University of Southern California’s Marshall School of Business. He is actively engaged in venture and entrepreneurial initiatives in the Southern California area and serves on the board of a privately-held commercial real estate company.

What is Anthony Bergmann's net worth?

The estimated net worth of Anthony Bergmann is at least $261.77 thousand as of March 31st, 2026. Bergmann owns 8,223 shares of Capricor Therapeutics stock worth more than $261,771 as of April 8th. This net worth evaluation does not reflect any other assets that Bergmann may own. Learn More about Anthony Bergmann's net worth.

How do I contact Anthony Bergmann?

The corporate mailing address for Bergmann and other Capricor Therapeutics executives is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. Capricor Therapeutics can also be reached via phone at 310-358-3200 and via email at [email protected]. Learn More on Anthony Bergmann's contact information.

Has Anthony Bergmann been buying or selling shares of Capricor Therapeutics?

Anthony Bergmann has not been actively trading shares of Capricor Therapeutics during the last quarter. Most recently, Anthony Bergmann sold 25,000 shares of the business's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.13, for a transaction totalling $753,250.00. Following the completion of the sale, the chief financial officer now directly owns 8,223 shares of the company's stock, valued at $247,758.99. Learn More on Anthony Bergmann's trading history.

Who are Capricor Therapeutics' active insiders?

Capricor Therapeutics' insider roster includes Paul Auwaerter (Director), Anthony Bergmann (CFO), and David Musket (Director). Learn More on Capricor Therapeutics' active insiders.

Are insiders buying or selling shares of Capricor Therapeutics?

During the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 147,529 shares worth more than $4,509,940.10. The most recent insider tranaction occured on April, 2nd when Director Karimah Es Sabar sold 7,529 shares worth more than $240,928.00. Insiders at Capricor Therapeutics own 10.5% of the company. Learn More about insider trades at Capricor Therapeutics.

Information on this page was last updated on 4/2/2026.

Anthony Bergmann Insider Trading History at Capricor Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/31/2026Sell25,000$30.13$753,250.008,223View SEC Filing Icon  
3/16/2016Buy2,030$2.40$4,872.002,030View SEC Filing Icon  
See Full Table

Anthony Bergmann Buying and Selling Activity at Capricor Therapeutics

This chart shows Anthony Bergmann's buying and selling at Capricor Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Capricor Therapeutics Company Overview

Capricor Therapeutics logo
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Read More

Today's Range

Now: $31.60
Low: $31.29
High: $33.00

50 Day Range

MA: $27.71
Low: $21.57
High: $33.57

2 Week Range

Now: $31.60
Low: $4.30
High: $40.37

Volume

639,962 shs

Average Volume

1,358,890 shs

Market Capitalization

$1.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48